Maria J. Sambade
YOU?
Author Swipe
View article: Shared PRAME Epitopes are T-Cell Targets in NUT Carcinoma
Shared PRAME Epitopes are T-Cell Targets in NUT Carcinoma Open
Background NUT carcinoma is a rare but highly lethal solid tumor without an effective standard of care. NUT carcinoma is caused by bromodomain-containing NUTM1 fusion oncogenes, most commonly BRD4::NUTM1 . BRD4::NUTM1 recruits p300 to acet…
View article: 848 Predictions of endogenous neoantigens from varied genomic sources in a syngeneic murine cancer model
848 Predictions of endogenous neoantigens from varied genomic sources in a syngeneic murine cancer model Open
Background Current immune checkpoint inhibitor immunotherapy relies on the presence of a pool of pre-existing neoantigen-specific T cells that can be unsuppressed and leveraged to eliminate cancer cells. However, in many patients in many c…
View article: Supplemental Figures S1-S9 from Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of <i>BRCA</i>-Mutated and <i>BRCA</i>–Wild-Type Triple-Negative Breast Cancer
Supplemental Figures S1-S9 from Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of <i>BRCA</i>-Mutated and <i>BRCA</i>–Wild-Type Triple-Negative Breast Cancer Open
This file contains the compiled Supplemental Figures S1-S9. Figure S1 is a flowchart describing the process of normalizing the microarray data for the SUM149 model for the different scanners used. Figure S2 depicts the scanner differences …
View article: Supplemental Table from Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of <i>BRCA</i>-Mutated and <i>BRCA</i>–Wild-Type Triple-Negative Breast Cancer
Supplemental Table from Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of <i>BRCA</i>-Mutated and <i>BRCA</i>–Wild-Type Triple-Negative Breast Cancer Open
This file contains the differentially expressed genes and enriched pathways lists from the gene expression microarray analyses in Supplemental Table S1, with sample information in S1a. Lists are for the following comparisons: SUM149 Contro…
View article: Supplemental Table from Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of <i>BRCA</i>-Mutated and <i>BRCA</i>–Wild-Type Triple-Negative Breast Cancer
Supplemental Table from Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of <i>BRCA</i>-Mutated and <i>BRCA</i>–Wild-Type Triple-Negative Breast Cancer Open
This file contains the differentially expressed genes and enriched pathways lists from the gene expression microarray analyses in Supplemental Table S1, with sample information in S1a. Lists are for the following comparisons: SUM149 Contro…
View article: Supplemental Figure Legends from Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of <i>BRCA</i>-Mutated and <i>BRCA</i>–Wild-Type Triple-Negative Breast Cancer
Supplemental Figure Legends from Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of <i>BRCA</i>-Mutated and <i>BRCA</i>–Wild-Type Triple-Negative Breast Cancer Open
This file contains the figure legends for Supplemental Figures S1-S9.
View article: Supplemental Figures S1-S9 from Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of <i>BRCA</i>-Mutated and <i>BRCA</i>–Wild-Type Triple-Negative Breast Cancer
Supplemental Figures S1-S9 from Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of <i>BRCA</i>-Mutated and <i>BRCA</i>–Wild-Type Triple-Negative Breast Cancer Open
This file contains the compiled Supplemental Figures S1-S9. Figure S1 is a flowchart describing the process of normalizing the microarray data for the SUM149 model for the different scanners used. Figure S2 depicts the scanner differences …
View article: Supplemental Methods from Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of <i>BRCA</i>-Mutated and <i>BRCA</i>–Wild-Type Triple-Negative Breast Cancer
Supplemental Methods from Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of <i>BRCA</i>-Mutated and <i>BRCA</i>–Wild-Type Triple-Negative Breast Cancer Open
This file contains additional details on the microarray analysis and normalization.
View article: Supplemental Figure Legends from Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of <i>BRCA</i>-Mutated and <i>BRCA</i>–Wild-Type Triple-Negative Breast Cancer
Supplemental Figure Legends from Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of <i>BRCA</i>-Mutated and <i>BRCA</i>–Wild-Type Triple-Negative Breast Cancer Open
This file contains the figure legends for Supplemental Figures S1-S9.
View article: Data from Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of <i>BRCA</i>-Mutated and <i>BRCA</i>–Wild-Type Triple-Negative Breast Cancer
Data from Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of <i>BRCA</i>-Mutated and <i>BRCA</i>–Wild-Type Triple-Negative Breast Cancer Open
Patients with breast cancer brain metastases have extremely limited survival and no approved systemic therapeutics. Triple-negative breast cancer (TNBC) commonly metastasizes to the brain and predicts poor prognosis. TNBC frequently harbor…
View article: Supplemental Methods from Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of <i>BRCA</i>-Mutated and <i>BRCA</i>–Wild-Type Triple-Negative Breast Cancer
Supplemental Methods from Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of <i>BRCA</i>-Mutated and <i>BRCA</i>–Wild-Type Triple-Negative Breast Cancer Open
This file contains additional details on the microarray analysis and normalization.
View article: Data from Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of <i>BRCA</i>-Mutated and <i>BRCA</i>–Wild-Type Triple-Negative Breast Cancer
Data from Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of <i>BRCA</i>-Mutated and <i>BRCA</i>–Wild-Type Triple-Negative Breast Cancer Open
Patients with breast cancer brain metastases have extremely limited survival and no approved systemic therapeutics. Triple-negative breast cancer (TNBC) commonly metastasizes to the brain and predicts poor prognosis. TNBC frequently harbor…
View article: Impact of prior systemic therapy on lymphocytic infiltration in surgically resected breast cancer brain metastases
Impact of prior systemic therapy on lymphocytic infiltration in surgically resected breast cancer brain metastases Open
View article: Comprehensive Analysis of the Immunogenomics of Triple-Negative Breast Cancer Brain Metastases From LCCC1419
Comprehensive Analysis of the Immunogenomics of Triple-Negative Breast Cancer Brain Metastases From LCCC1419 Open
BackgroundTriple negative breast cancer (TNBC) is an aggressive variant of breast cancer that lacks the expression of estrogen and progesterone receptors (ER and PR) and HER2. Nearly 50% of patients with advanced TNBC will develop brain me…
View article: BSCI-06 COMPREHENSIVE ANALYSIS OF THE IMMUNOGENOMICS OF TRIPLE NEGATIVE BREAST CANCER BRAIN METASTASES FROM LCCC1419
BSCI-06 COMPREHENSIVE ANALYSIS OF THE IMMUNOGENOMICS OF TRIPLE NEGATIVE BREAST CANCER BRAIN METASTASES FROM LCCC1419 Open
BACKGROUND Triple negative breast cancer (TNBC) lacks expression of hormone receptors (estrogen and progesterone receptors, ER and PR) and HER2. Almost 50% of patients with metastatic TNBC will develop brain metastases (BrM), often with co…
View article: Comprehensive Analysis of the Immunogenomics of Triple-Negative Breast Cancer Brain Metastases From LCCC1419
Comprehensive Analysis of the Immunogenomics of Triple-Negative Breast Cancer Brain Metastases From LCCC1419 Open
Background Triple negative breast cancer (TNBC) is an aggressive variant of breast cancer that lacks the expression of estrogen and progesterone receptors (ER and PR) and HER2. Nearly 50% of patients with advanced TNBC will develop brain m…
View article: A SARS-CoV-2 peptide vaccine which elicits T-cell responses in mice but does not protect against infection or disease
A SARS-CoV-2 peptide vaccine which elicits T-cell responses in mice but does not protect against infection or disease Open
We vaccinated BALB/c mice with peptides derived from the SARS-CoV-2 proteome selected in silico to elicit T-cell responses and/or B-cell responses against linear epitopes. These peptides were administered in combination with either of two …
View article: Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer
Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer Open
Purpose Triple negative breast cancer (TNBC) is characterized by the presence of immune cells in the tumor microenvironment, however, the response to single-agent immune checkpoint inhibitor (ICI) therapy is modest. Preclinical models have…
View article: Landscape and selection of vaccine epitopes in SARS-CoV-2
Landscape and selection of vaccine epitopes in SARS-CoV-2 Open
View article: Additional file 2 of Landscape and selection of vaccine epitopes in SARS-CoV-2
Additional file 2 of Landscape and selection of vaccine epitopes in SARS-CoV-2 Open
Additional file 2: Table S1. All SARS-CoV-2 MHC-I ligands contained in the top 5% of U.S. HLA alleles. Table S2. All SARS-CoV-2 MHC-II ligands contained in the top 5% of U.S. HLA alleles. Table S3. All SARS-CoV-2 MHC-I ligands contained in…
View article: Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK
Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK Open
We recently showed that lapatinib, an EGFR/HER2 inhibitor, radiosensitized breast cancer cells of the basal and HER2+ subtypes. The purpose of this study was to identify the downstream signaling pathways responsible for lapatinib-mediated …
View article: Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032
Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032 Open
To assess the relative radiosensitivities of a large collection of melanoma cell lines and to determine whether pharmacologic inhibition of mutant B-RAF with PLX-4032 can radiosensitize B-Raf+ melanoma cells.
View article: A prognostic signature of defective p53-dependent G1 checkpoint function in melanoma cell lines: A signature of defective p53 function in melanoma
A prognostic signature of defective p53-dependent G1 checkpoint function in melanoma cell lines: A signature of defective p53 function in melanoma Open
Melanoma cell lines and normal human melanocytes were assayed for p53-dependent G1 checkpoint response to ionizing radiation-induced DNA damage. Sixty six percent of melanoma cell lines displayed a defective G1 checkpoint. Checkpoint funct…
View article: Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma
Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma Open
Somatic sequencing of cancers has produced new insight into tumorigenesis, tumor heterogeneity, and disease progression, but the vast majority of genetic events identified are of indeterminate clinical significance. Here we describe a Next…
View article: MERTK receptor tyrosine kinase is a therapeutic target in melanoma
MERTK receptor tyrosine kinase is a therapeutic target in melanoma Open
Metastatic melanoma is one of the most aggressive forms of cutaneous cancers. Although recent therapeutic advances have prolonged patient survival, the prognosis remains dismal. C-MER proto-oncogene tyrosine kinase (MERTK) is a receptor ty…
View article: Lapatinib in Combination With Radiation Diminishes Tumor Regrowth in HER2+ and Basal-Like/EGFR+ Breast Tumor Xenografts
Lapatinib in Combination With Radiation Diminishes Tumor Regrowth in HER2+ and Basal-Like/EGFR+ Breast Tumor Xenografts Open
To determine whether lapatinib, a dual epidermal growth factor receptor (EGFR)/HER2 kinase inhibitor, can radiosensitize EGFR+ or HER2+ breast cancer xenografts.
View article: 478 Translation of a therapeutic neoantigen vaccine workflow to SARS-CoV-2 vaccine development
478 Translation of a therapeutic neoantigen vaccine workflow to SARS-CoV-2 vaccine development Open
Background There is an urgent need for a vaccine with efficacy against SARS-CoV-2. We hypothesize that peptide vaccines containing epitope regions optimized for concurrent B cell, CD4+ T cell, and CD8+ T cell stimulation would drive both h…
View article: 258 Scientific correlatives from LCCC 1525: a phase II study of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer
258 Scientific correlatives from LCCC 1525: a phase II study of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer Open
Background In metastatic triple negative breast cancer (mTNBC), median progression-free survival (PFS) with chemotherapy alone is approximately 2–4 months1 and improvements with single agent checkpoint inhibitors (CI) are limite…
View article: Landscape and Selection of Vaccine Epitopes in SARS-CoV-2
Landscape and Selection of Vaccine Epitopes in SARS-CoV-2 Open
There is an urgent need for a vaccine with efficacy against SARS-CoV-2. We hypothesize that peptide vaccines containing epitope regions optimized for concurrent B cell, CD4 + T cell, and CD8 + T cell stimulation would drive both humoral an…
View article: Efficacy and pharmacokinetics of a modified acid-labile docetaxel-PRINT ® nanoparticle formulation against non-small-cell lung cancer brain metastases
Efficacy and pharmacokinetics of a modified acid-labile docetaxel-PRINT ® nanoparticle formulation against non-small-cell lung cancer brain metastases Open
Particle Replication in Nonwetting Templates (PRINT®) PLGA nanoparticles of docetaxel and acid-labile C2-dimethyl-Si-Docetaxel were evaluated with small molecule docetaxel as treatments for non-small-cell lung cancer brain metastases.